Serum Amyloid P Ameliorates Radiation-induced Oral Mucositis and Fibrosis

Overview

Journal Fibrogenesis Tissue Repair

Publisher Biomed Central

Date 2010 Jul 7

PMID 20602770

Citations 17

Authors

Lynne A Murray

Michael S Kramer

David P Hesson

Brynmor A Watkins

Edward G Fey

Rochelle L Argentieri

Furquan Shaheen

Darryl A Knight

Stephen T Sonis

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the effect of the anti-fibrotic protein serum amyloid P (SAP) on radiation-induced oral mucositis (OM) and fibrosis in a hamster cheek-pouch model.

Experimental Design: Hamsters received a single dose of radiation (40 Gy) to the left everted cheek pouch to induce significant OM. The protective therapeutic potential of SAP was evaluated using varying dosing regimens. The extent of OM was measured using a validated six-point scoring scheme ranging from 0 (normal tissue, no mucositis) to 5 (complete ulceration). Fibrotic remodeling was also visualized histologically and quantified at later time points using collagen gene expression.

Results: SAP treatment attenuated the profile of radiation-induced oral mucositis by delaying the time of onset, reducing the peak value, and enhancing the resolution of injury. The peak mucositis score was reduced by approximately 0.5 grade in SAP-treated animals. The number of animal days with a score of >/= 3 was reduced by 48% in the SAP-treated group, compared with the saline control group (P < 0.01). SAP also inhibited the extent of tissue remodeling and decreased radiation-induced increases in myofibroblast number. Attenuated collagen deposition and gene expression was also observed in the cheek pouches of hamsters treated with SAP at both 16 and 28 days post-radiation.

Conclusions: SAP treatment significantly attenuated radiation-induced injury. In particular, SAP attenuated the severity of OM and inhibited pathogenic remodeling. This suggests that SAP may be a useful therapy for the palliation of side effects observed during treatment for head and neck cancer.

Citing Articles

SAP deletion promotes malignant insulinoma progression by inducing CXCL12 secretion from CAFs via the CXCR4/p38/ERK signalling pathway.

Jiang G, Xu S, Mai X, Tu J, Wang L, Wang L J Cell Mol Med. 2024; 28(10):e18397.

PMID: 38766687 PMC: 11103456. DOI: 10.1111/jcmm.18397.

Inhibitors of the Sialidase NEU3 as Potential Therapeutics for Fibrosis.

Karhadkar T, Chen W, Pilling D, Gomer R Int J Mol Sci. 2023; 24(1).

PMID: 36613682 PMC: 9820515. DOI: 10.3390/ijms24010239.

SAP deficiency aggravates periodontitis possibly via C5a-C5aR signaling-mediated defective macrophage phagocytosis of Porphyromonas gingivalis.

Wang L, Liang D, Huang Y, Chen Y, Yang X, Huang Z J Adv Res. 2022; 50:55-68.

PMID: 36243399 PMC: 10403661. DOI: 10.1016/j.jare.2022.10.003.

Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.

Karhadkar T, Pilling D, Gomer R PLoS One. 2021; 16(1):e0245924.

PMID: 33481950 PMC: 7822324. DOI: 10.1371/journal.pone.0245924.

The Development of Serum Amyloid P as a Possible Therapeutic.

Pilling D, Gomer R Front Immunol. 2018; 9:2328.

PMID: 30459752 PMC: 6232687. DOI: 10.3389/fimmu.2018.02328.

References

Peterson D . Research advances in oral mucositis. Curr Opin Oncol. 1999; 11(4):261-6. DOI: 10.1097/00001622-199907000-00005. View

Murray L, Rosada R, Moreira A, Joshi A, Kramer M, Hesson D . Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010; 5(3):e9683. PMC: 2837381. DOI: 10.1371/journal.pone.0009683. View

Weigert A, Jennewein C, Brune B . The liaison between apoptotic cells and macrophages--the end programs the beginning. Biol Chem. 2009; 390(5-6):379-90. DOI: 10.1515/BC.2009.048. View

Hwang D, Popat R, Bragdon C, ODonnell K, Sonis S . Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(3):321-9. DOI: 10.1016/j.tripleo.2004.09.018. View

Plevova P . Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol. 2000; 35(5):453-70. DOI: 10.1016/s1368-8375(99)00033-0. View

Pilling D, Buckley C, Salmon M, Gomer R . Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003; 171(10):5537-46. PMC: 4482350. DOI: 10.4049/jimmunol.171.10.5537. View

Gregory C, Devitt A . The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?. Immunology. 2004; 113(1):1-14. PMC: 1782541. DOI: 10.1111/j.1365-2567.2004.01959.x. View

Zeisberg M, Yang C, Martino M, Duncan M, Rieder F, Tanjore H . Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 2007; 282(32):23337-47. DOI: 10.1074/jbc.M700194200. View

Logan R, Stringer A, Bowen J, Yeoh A, Gibson R, Sonis S . The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007; 33(5):448-60. DOI: 10.1016/j.ctrv.2007.03.001. View

10.

Handschel J, Sunderkotter C, Prott F, Meyer U, Kruse-Losler B, Joos U . Increase of RM3/1-positive macrophages in radiation-induced oral mucositis. J Pathol. 2001; 193(2):242-7. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH754>3.0.CO;2-P. View

11.

Castano A, Lin S, Surowy T, Nowlin B, Turlapati S, Patel T . Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med. 2010; 1(5):5ra13. PMC: 2852889. DOI: 10.1126/scitranslmed.3000111. View

12.

Sonis S, Elting L, Keefe D, Peterson D, Schubert M, Hauer-Jensen M . Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100(9 Suppl):1995-2025. DOI: 10.1002/cncr.20162. View

13.

Breathnach S, Kofler H, Sepp N, Ashworth J, Woodrow D, Pepys M . Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med. 1989; 170(4):1433-8. PMC: 2189460. DOI: 10.1084/jem.170.4.1433. View

14.

Chi K, Chen C, Chan W, Chow K, Chen S, Yen S . Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 1995; 13(10):2620-8. DOI: 10.1200/JCO.1995.13.10.2620. View

15.

Haudek S, Xia Y, Huebener P, Lee J, Carlson S, Crawford J . Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A. 2006; 103(48):18284-9. PMC: 1643845. DOI: 10.1073/pnas.0608799103. View

16.

Sonis S . Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34(1):39-43. DOI: 10.1016/s1368-8375(97)00053-5. View

17.

Wymenga A, van der Graaf W, Hofstra L, Spijkervet F, Timens W, Timmer-Bosscha H . Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999; 5(6):1363-8. View

18.

Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B . Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant. 1998; 22(8):781-5. DOI: 10.1038/sj.bmt.1701434. View

19.

Knox J, Puodziunas A, Feld R . Chemotherapy-induced oral mucositis. Prevention and management. Drugs Aging. 2000; 17(4):257-67. DOI: 10.2165/00002512-200017040-00002. View

20.

Antin J, Lee S, Neuberg D, Alyea E, Soiffer R, Sonis S . A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 29(5):373-7. DOI: 10.1038/sj.bmt.1703394. View